Role of AMPK in pancreatic beta cell function

Mol Cell Endocrinol. 2013 Feb 25;366(2):127-34. doi: 10.1016/j.mce.2012.06.020. Epub 2012 Jul 3.

Abstract

Pharmacological activation of AMP activated kinase (AMPK) by metformin has proven to be a beneficial therapeutic approach for the treatment of type II diabetes. Despite improved glucose regulation achieved by administration of small molecule activators of AMPK, the potential negative impact of enhanced AMPK activity on insulin secretion by the pancreatic beta cell is an important consideration. In this review, we discuss our current understanding of the role of AMPK in central functions of the pancreatic beta cell, including glucose-stimulated insulin secretion (GSIS), proliferation, and survival. In addition we discuss the controversy surrounding the role of AMPK in insulin secretion, underscoring the merits and caveats of methods used to date.

Publication types

  • Review

MeSH terms

  • AMP-Activated Protein Kinases / genetics
  • AMP-Activated Protein Kinases / metabolism*
  • Animals
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / enzymology*
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / pathology
  • Enzyme Activation / drug effects
  • Gene Expression / drug effects
  • Glucose / metabolism*
  • Glucose / pharmacology
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Insulin / biosynthesis*
  • Insulin / metabolism
  • Insulin Secretion
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / enzymology*
  • Insulin-Secreting Cells / pathology
  • Metformin / pharmacology
  • Metformin / therapeutic use
  • Mice
  • Mice, Knockout

Substances

  • Hypoglycemic Agents
  • Insulin
  • Metformin
  • AMP-Activated Protein Kinases
  • Glucose